Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Edgewise Therapeutics has raised $200.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2025.
Edgewise Therapeutics's investors include RA Capital Management, Cormorant Asset Management, Citadel, U.S. Venture Partners, Janus Henderson Investors.
Edgewise Therapeutics is headquartered in Boulder, United States.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Edgewise Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Edgewise Therapeutics — Funding & Investors." VCBacked, April 2, 2025, https://www.vcbacked.co/company/edgewise-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). Edgewise Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/edgewise-therapeutics
{{cite web |title=Edgewise Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/edgewise-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated